Shield Therapeutics received notification from the FDA that it has granted approval for Feraccru, or Accrufer as the product will be marketed in the US market. The FDA granted a broader than expected label, given Feraccru’s tolerability profile and efficacy – the treatment of Iron Deficiency (ID) with or without anaemia – with the label indicating its use for as long as necessary to restore iron levels, implying a chronic therapy. This at least doubles the potential addressa
26 Jul 2019
Shield Therapeutics - FDA approval and with a broad label
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - FDA approval and with a broad label
Shield Therapeutics Plc (STX:LON) | 1.3 0 (-7.0%) | Mkt Cap: 10.4m
- Published:
26 Jul 2019 -
Author:
Mark Brewer -
Pages:
10
Shield Therapeutics received notification from the FDA that it has granted approval for Feraccru, or Accrufer as the product will be marketed in the US market. The FDA granted a broader than expected label, given Feraccru’s tolerability profile and efficacy – the treatment of Iron Deficiency (ID) with or without anaemia – with the label indicating its use for as long as necessary to restore iron levels, implying a chronic therapy. This at least doubles the potential addressa